Baxter International has collaborated with Chatham Therapeutics for the development and commercialization of factor IX hemophilia B gene therapy treatment.
According to the agreement, the companies will investigate the next generation of the Biological Nano Particles, Chatham's recombinant adeno-associated virus-based gene therapy technology, through US-based hemophilia B clinical trials.
Baxter's BioScience business president Ludwig Hantson said the collaboration helps the company to advance treatment options for patients living with hemophilia.
Baxter obtained global rights for the marketing and commercialization of the new treatment.
Baxter made upfront cash payment of $25m for the development and advancement of the program through early clinical trials, and will record the amount as a special pre-tax in-process research and development charge in the second quarter of 2012.
Depending on certain development and commercial milestones, Baxter may make additional payments over the next several years.
Chatham co-founder and AskBio vice president Jade Samulski said, ''This agreement initiates a clinical development collaboration dedicated to advancing a potential long-term treatment paradigm for hemophilia patients.''
